Ningbo Menovo Pharmaceutical (603538) Fundamentals 2026 — P/E 58.6x, Revenue Analysis | SniperIQ
Ningbo Menovo Pharmaceutical (603538) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥9.9B, trading at ¥29.23 on the SHH. This SniperIQ fundamentals page covers Ningbo Menovo Pharmaceutical's valuation (P/E 58.6x, P/B 2.7x), profitability (net margin 7.2%), revenue (¥1.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Ningbo Menovo Pharmaceutical's market cap?
Ningbo Menovo Pharmaceutical (603538) has a market capitalization of approximately ¥9.9B, trading at ¥29.23 on the SHH. Market cap moves with the live share price.
What is Ningbo Menovo Pharmaceutical's P/E ratio?
Ningbo Menovo Pharmaceutical's trailing twelve-month P/E ratio is 58.6x, with a price-to-book (P/B) of 2.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Ningbo Menovo Pharmaceutical?
Ningbo Menovo Pharmaceutical runs a net profit margin of 7.2%, a gross margin of 34.0%, and an operating margin of 8.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Ningbo Menovo Pharmaceutical generate?
Ningbo Menovo Pharmaceutical reported revenue of ¥1.5B for fiscal year 2025, with net income of ¥102M and earnings per share (EPS) of 0.48. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Ningbo Menovo Pharmaceutical pay a dividend?
Ningbo Menovo Pharmaceutical offers a trailing dividend yield of about 0.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Ningbo Menovo Pharmaceutical financially healthy?
Ningbo Menovo Pharmaceutical carries a debt-to-equity ratio of 0.49x and a current ratio of 1.45x, with a market beta of -0.05. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Ningbo Menovo Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Ningbo Menovo Pharmaceutical (603538) the key facts are: market cap ¥9.9B, P/E 58.6x, revenue ¥1.5B, 52-week range 13.55-50.27857. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Ningbo Menovo Pharmaceutical's full fundamentals live
Get Ningbo Menovo Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.